Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Biotech
Nanobiotix finds new way to source cash from J&J-partnered drug
Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug.
James Waldron
Oct 31, 2025 6:05am
J&J MedTech, Verily pen Nvidia deals
Oct 29, 2025 8:45am
J&J reveals plan to spin off its $9B orthopedics business
Oct 14, 2025 11:30am
J&J eyes takeover of immunology partner Protagonist: WSJ
Oct 10, 2025 2:30pm
BMS, Takeda join peers in push to improve AI by pooling data
Oct 1, 2025 10:34am
J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial
Sep 17, 2025 9:45am
